news

Portfolio company Quartet Medicine Announces Strategic Partnership with Merck

https://quartetmedicine.com/wp-content/uploads/2016/01/Quartet-Medicine-Announces-Strategic-Partnership-with-Merck.pdf

Apollo Endosurgery receives FDA approval for an innovative non-surgical weight loss solution

http://apolloendo.com/apollo-endosurgery-inc-announces-fda-approval-of-the-orbera-intragastric-balloon-a-non-surgical-solution-to-assist-patients-in-weight-loss/

Portfolio company Tigercat Pharma announces positive Phase II results

http://tigercatpharma.com/2014/12/17/velocity-pharmaceutical-development-llc-and-tigercat-pharma-inc-announce-phase-2-results-for-vpd-737-in-patients-with-chronic-pruritus/#more-809

Apollo Endosurgery’s LAP-BAND System featured on “The Dr. Oz Show”

http://apolloendo.com/the-dr-oz-show-features-lap-band-system/

miRagen compound reverses pulmonary fibrosis

http://miragentherapeutics.com/news-release/research-findings-demonstrate-miragen-therapeutics-synthetic-microrna-29-mimic-promir-29-reverses-pulmonary-fibrosis/

BiO2 enrolls subjects in Early Feasibility Pilot Study

http://www.prnewswire.com/news-releases/bio2-medical-enrolls-subjects-in-the-new-us-fda-early-feasibility-pilot-study-for-the-angel-catheter-250851491.html

Tigercat Pharma doses first patient in Prurigo Nodularis Phase II Study

http://www.vpd.net/press_releases/VPD_8.4.2014.html

Portfolio company Apollo Endosurgery completes acquisition of obesity intervention division

http://apolloendo.com/apollo-endosurgery-completes-acquisition-of-allergan-inc-s-obesity-intervention-division/

Remeditex supports promising research with San Antonio scientist.

http://www.uthscsa.edu/hscnews/singleformat2.asp?newID=4320

Portfolio company miRagen named one of the most promising biotech companies of 2012.

http://www.miragentherapeutics.com/122/September 19, 2012/

Remeditex Ventures funds innovative medical device company.

http://www.bio2medical.com/news/bio2-medicalraises12m/

Remeditex Ventures leads Series B financing in Boulder based microRNA company, miRagen.

http://www.miragentherapeutics.com/116/April 24, 2012/

Remeditex is a key investor in an Austin based medical device company.

http://www.apolloendo.com/News---Events/Press-Releases/Apollo-Endosurgery-Announces-$47-6M-Financing.aspx

Remeditex supports an early stage Dallas-based oncology company

http://www.prnewswire.com/news-releases/peloton-therapeutics-completes-18-million-series-a-financing-126237918.html